ArticleCellular and molecular life sciences : CMLS2026
Interaction between HIV-1 Tat and EBV Zta favours immune escape of B cells by downregulating HLA-ABC expression.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multiple Sclerosis and Viruses: « Liaisons Dangereuses ».Reviews in medical virology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Both Human immunodeficiency virus (HIV) and Epstein-Barr Virus (EBV) are associated with an increased risk of malignancies. HIV infection is associated with EBV reactivation and an increase in EBV viral loads in saliva and blood, and people living with HIV frequently develop EBV-associated B-cell malignancies. In this study, we aimed to investigate the involvement of HIV-1 and EBV co-existence in the development of B-cell malignancies. To do so, we focused our attention on the two viral transcriptional activators (HIV-1 Tat and EBV Zta) and analyzed their possible interaction since they both have cell-penetration domains and can be found simultaneously in the blood or cells of people living with HIV. We investigated the interaction of Tat and Zta using co-immunoprecipitation, in vitro binding, YFP reconstitution assay and FRET. We found that they bind each other in human B cells and blood serum. Tat and Zta interaction was also observed in a serum sample from one HIV-positive individual. YFP reconstitution demonstrated that this interaction occurred predominantly in the nucleus, indicating that it might affect the host genome. We further analyzed the effects of Tat and Zta on primary and EBV-transformed human B cells by RNA-sequencing and found that the combined Tat and Zta action in B cells differed from a single action of the two proteins. A subset of genes, activated by Tat or Zta alone, that trigger an immune response and antigen presentation in B cells, remained unchanged when the two proteins were combined. B cells, treated or transfected with Tat and Zta, exhibited a substantial decrease in HLA-ABC (MHC class I) expression, a critical component of the antigen processing and presentation pathway. Our findings suggest that the reduction of total HLA-ABC levels in B cells upon Tat and Zta interaction might be linked to HLA-ABC proteasomal degradation. Furthermore, HLA-ABC downregulation induced by Tat and Zta interaction conferred protection against cytotoxic T cell recognition of EBV-infected B cells. To conclude, we demonstrated for the first time that HIV-1 Tat and EBV Zta interacted directly in B cells and blood serum; this interaction can be found in people with HIV. This interaction brings about immune evasion of EBV-infected or transformed B cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.